{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:00:51Z","timestamp":1793818851061,"version":"4.6.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>The Dermatology Life Quality Index (DLQI) is commonly used to assess the quality of life of patients with skin diseases. Clinical trials confirm the positive effect of the use of biologics and new molecules on the quality of life of patients with plaque psoriasis.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Main objectives<\/jats:title><jats:p>Investigation of the effect of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib on Health-Related Quality of Life (HRQOL) measured by the DLQI in adult plaque psoriatic patients with respect to the patients\u2019 race, type of used agent\/placebo, agent\u2019s dosage and treatment duration as well as the DLQI score prior to and after commencement of treatment.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Material and methods<\/jats:title><jats:p>Systematic literature searching for referential papers written in English using four databases: PubMed, EMBASE, Scopus, ClinicalTrials.gov as well as<jats:strike>and<\/jats:strike>manual searching (Google) Cochran\u2019s (Q) and I<jats:sup>2<\/jats:sup>tests were used for evaluation of heterogeneity or the degree of variation in the true effect size estimates between the analysed studies. The standardized mean difference (the SMD; Hedge\u2019s g score) was applied to measure the differences between the two means (i.e. two groups: treated vs non-treated or treated vs placebo). The data coding and Hedge's g values were calculated according to the guidance of MetaXL software version 5.3.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Main results<\/jats:title><jats:p>43 studies, in total 25,898 individuals, were evaluated by the DLQI and weighted mean scores were derived for the analysis. The mean DLQI scores ranged from 6.83 to 17.8 with the overall DLQI score of 12.12 (95%CI: 11.24 to 13.06). A random-effects model demonstrated significant considerable heterogeneity of the study results (I<jats:sup>2<\/jats:sup>= 98%; p&lt;0.001).<\/jats:p><\/jats:sec><jats:sec id=\"sec005\"><jats:title>Conclusion<\/jats:title><jats:p>Infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib in adult plaque psoriatic patients improved HRQOL measured by the DLQI. The patients with lower quality of life before treatment obtained better results.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0241604","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T18:48:49Z","timestamp":1607021329000},"page":"e0241604","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-4878","authenticated-orcid":true,"given":"Anna","family":"Karpi\u0144ska-Mirecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Bartosi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-9870","authenticated-orcid":true,"given":"Dorota","family":"Krasowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"6","key":"pone.0241604.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis Pathogenesis and Treatment","volume":"20","author":"A Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"pone.0241604.ref002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3899\/jrheum.150638","article-title":"Concept of remission in Chronic Plaque Psoriasis","volume":"93","author":"P Gisondi","year":"2015","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"pone.0241604.ref003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: results from a phase 3, randomized, placebo- controlled, double- blind study","volume":"31","author":"L Cai","year":"2017","journal-title":"J Eur Acad Dermatol and Venereol"},{"issue":"6","key":"pone.0241604.ref004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/abd1806-4841.20165080","article-title":"Psoriasis comorbidities: complications and benefits of immunobiological treatment","volume":"91","author":"A Carvalho","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"1","key":"pone.0241604.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"U Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"pone.0241604.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms18112297","article-title":"Old and New Biological Therapies for Psoriasis","volume":"18","author":"K Ronholt","year":"2017","journal-title":"Int J Mol Sci"},{"key":"pone.0241604.ref007","first-page":"329","article-title":"Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological society. Part II: Moderate to severe psoriasis","volume":"3","author":"A Reich","year":"2018","journal-title":"Dermatol Rev"},{"issue":"11","key":"pone.0241604.ref008","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/1744666X.2018.1524755","article-title":"Golimumab in the treatment of psoriatic arthritis","volume":"14","author":"TJ Love","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"pone.0241604.ref009","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis","volume":"12","author":"I Haugh","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"pone.0241604.ref010","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jdv.14377","article-title":"Impact of ixekizumab treatment on skin- related personal relationship difficulties in moderate to severe psoriasis patients: 12 weeks from two Phase 3 trials","volume":"31","author":"L Guenther","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"pone.0241604.ref011","first-page":"123","article-title":"New biologics in psoriasis: an update on IL- 23 and IL- 17 inhibitors","volume":"99","author":"J Dong","year":"2017","journal-title":"Cutis"},{"issue":"9","key":"pone.0241604.ref012","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"A Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"pone.0241604.ref013","first-page":"1","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The Prisma Statement.","volume":"6","author":"The Prisma Group","year":"2009","journal-title":"PLos Med"},{"issue":"16","key":"pone.0241604.ref014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in metaanalysis","volume":"1","author":"L Furura-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"issue":"6","key":"pone.0241604.ref015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient\u2010reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"D Revicki","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"pone.0241604.ref016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate- to\u2013severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo- controlled multicenter trial","volume":"59","author":"H Torii","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"6","key":"pone.0241604.ref017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/120347541201600609","article-title":"Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practise","volume":"16","author":"R Vender","year":"2012","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"pone.0241604.ref018","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjd.14464","article-title":"Psychometric propertied of the Itch Numeric Rating Scale in patients with moderate- to severe plaque psoriasis","volume":"175","author":"AB Kimball","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"pone.0241604.ref019","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4103\/idoj.IDOJ_63_18","article-title":"Narrow band UVB Phototherapy does not consistenty improve Quality of Life in Psoriasis Patients: A Prospective Observational Study from Eastern India","volume":"9","author":"S Arora","year":"2018","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"pone.0241604.ref020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/ijdvl.IJDVL_425_16","article-title":"Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial","volume":"83","author":"SH Chua","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"pone.0241604.ref021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/idoj.IDOJ_330_16","article-title":"A real- world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis","volume":"8","author":"A Parthasaradhi","year":"2017","journal-title":"Indian Dermatol Online J"},{"issue":"7","key":"pone.0241604.ref022","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jdv.14832","article-title":"Real- world data on the efficacy and safety of apremilast in the patients with moderate to severe plaque psoriasis","volume":"32","author":"E Papadavid","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"pone.0241604.ref023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A pooled analysis of phase III studies","volume":"35","author":"A K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"issue":"11","key":"pone.0241604.ref024","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"S Imafuku","year":"2017","journal-title":"J Dermatol"},{"issue":"4","key":"pone.0241604.ref025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis -results of two phase 3 trials","volume":"371","author":"RG Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0241604.ref026","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate- to- severe plaques psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"M Sticherlig","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"pone.0241604.ref027","first-page":"325","article-title":"Effect of Tofacitinib withrawal and re-treatment on patient- reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"C Griffiths","year":"2017","journal-title":"J Eur Acad Dermatol an Venereol"},{"issue":"10","key":"pone.0241604.ref028","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study","volume":"30","author":"F Valenzuela","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"pone.0241604.ref029","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double blind, placebo- controlled multicenter trial","volume":"125","author":"HZ Yang","year":"2012","journal-title":"Chin Med J"},{"issue":"1","key":"pone.0241604.ref030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","article-title":"Adalimumab treatment is associated with improvement in health\u2010related quality of life in psoriasis: Patient\u2010reported outcomes from a Phase II randomized controlled trial","volume":"18","author":"R Shikiar","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"pone.0241604.ref031","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/1346-8138.13081","article-title":"TUR-PSO: A cross- sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey","volume":"43","author":"N Atakan","year":"2016","journal-title":"J Dermatol"},{"issue":"5","key":"pone.0241604.ref032","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate- to- severe plaque psoriasis: results of an open- label, active- controlled, randomized trial (RESTORE 1)","volume":"165","author":"J Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"7","key":"pone.0241604.ref033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/1346-8138.13214","article-title":"Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post- marketing surveillance","volume":"43","author":"H Torii","year":"2016","journal-title":"J Dermatol"},{"issue":"4","key":"pone.0241604.ref034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"27","author":"R Shikiar","year":"2006","journal-title":"Health and Qual Life Outcomes"},{"issue":"5","key":"pone.0241604.ref035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bjd.13065","article-title":"Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial","volume":"171","author":"B Zhu","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"pone.0241604.ref036","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis","volume":"137","author":"Z Jakbar-Lopez","year":"2017","journal-title":"J Incest Dermatol"},{"issue":"6","key":"pone.0241604.ref037","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1177\/0300060519847414","article-title":"Efficacy and Safety of Tofacitinib for the Treatment of Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis","volume":"47","author":"F Tian","year":"2019","journal-title":"J Int Res"},{"key":"pone.0241604.ref038","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in Patients- Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate -to -Severe Plaque Psoriasis: Results from the Phase III Voyage 1 and Voyage 2 Studies","volume":"20","author":"AW Armstrong","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"pone.0241604.ref039","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jaad.2018.03.047","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis","volume":"79","author":"C Zachariae","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"pone.0241604.ref040","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial","volume":"154","author":"K Reich","year":"2006","journal-title":"Br J Dermatol"},{"issue":"5","key":"pone.0241604.ref041","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life patients with severe psoriasis: a double -blind placebo controlled trial","volume":"152","author":"SR Feldman","year":"2005","journal-title":"Br J Dermatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T14:54:48Z","timestamp":1697295288000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241604"}},"subtitle":[],"editor":[{"given":"Ahmed","family":"Negida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241604","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}